Format

Send to

Choose Destination
Int J Behav Nutr Phys Act. 2018 Jun 7;15(1):49. doi: 10.1186/s12966-018-0686-0.

RiseTx: testing the feasibility of a web application for reducing sedentary behavior among prostate cancer survivors receiving androgen deprivation therapy.

Author information

1
Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON, Canada. linda.trinh@utoronto.ca.
2
Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON, Canada.
3
Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
4
Department of Medicine, University Health Network & University of Toronto, Toronto, ON, Canada.
5
Cancer Survivorship Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.
6
School of Kinesiology, University of British Columbia, Vancouver, BC, Canada.

Abstract

BACKGROUND:

Given the high levels of sedentary time and treatment-related side effects in prostate cancer survivors (PCS), interventions targeting sedentary behavior (SED) may be more sustainable compared to physical activity (PA).

PURPOSE:

To examine the feasibility of a web-based intervention (RiseTx) for reducing SED and increasing moderate-to-vigorous physical activity (MVPA) among PCS undergoing ADT. Secondary outcomes include changes in SED, MVPA, light intensity PA, and quality of life.

METHODS:

Forty-six PCS were recruited from two cancer centres in Toronto, Ontario, Canada between July 2015-October 2016. PCS were given an activity tracker (Jawbone), access to the RiseTx website program, and provided with a goal of increasing walking by 3000 daily steps above baseline levels over a 12-week period. A range of support tools were progressively released to reduce SED time (e.g., self-monitoring of steps) during the five-phase program. Objective measures of SED, MVPA, and daily steps were compared across the 12-week intervention using linear mixed models.

RESULTS:

Of the 46 PCS enrolled in the study, 42 completed the SED intervention, representing a 9% attrition rate. Measurement completion rates were 97 and 65% at immediately post-intervention and 12-week follow-up for all measures, respectively. Overall adherence was 64% for total number of logins (i.e., > 3 visits each week). Sample mean age was 73.2 ± 7.3 years, mean BMI was 28.0 ± 3.0 kg/m2, mean number of months since diagnosis was 93.6 ± 71.2, and 72% had ADT administered continuously. Significant reductions of 455.4 weekly minutes of SED time were observed at post-intervention (p = .005). Significant increases of + 44.1 for weekly minutes of MVPA was observed at immediately post-intervention (p = .010). There were significant increases in step counts of + 1535 steps from baseline to post-intervention (p < .001).

CONCLUSIONS:

RiseTx was successful in reducing SED and increasing MVPA in PCS. PCS were satisfied with the intervention and its components. Additional strategies may be needed though for maintenance of behavior change. The next step for RiseTx is to replicate these findings in a larger, randomized controlled trial that will have the potential for reducing sedentary time among PCS.

TRIAL REGISTRATION:

NCT03321149 (ClinicalTrials.gov Identifier).

KEYWORDS:

Feasibility, web-based, physical activity; Prostate cancer; Sedentary behavior

PMID:
29880049
PMCID:
PMC5992665
DOI:
10.1186/s12966-018-0686-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center